Glucoryl-M3 Tablet PR is a combination oral antihyperglycemic medication containing Glimepiride 3 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, enhancing peripheral glucose uptake, and improving insulin sensitivity. The synergistic action of these two agents provides effective control of blood glucose levels in patients inadequately managed by diet and exercise alone. Glucoryl-M3 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan, including lifestyle modifications such as diet and physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects include gastrointestinal disturbances such as nausea, vomiting, and diarrhea, as well as potential hypoglycemia due to glimepiride. Regular monitoring of blood glucose, renal function, and hepatic parameters is recommended during therapy. Dose adjustments may be necessary based on clinical response and tolerance. Glucoryl-M3 Tablet PR should be used under medical supervision to optimize therapeutic outcomes and minimize risks.